{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-23-000119","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.611788+00:00","generated_at":"2026-06-12T13:47:04.398697+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evolent Q2 revenue up 47% to $469M, raises 2023 Adj. EBITDA guidance; redeems $24.3M convertible notes","bullets":["Revenue $469.1M (+46.6% YoY); net loss $41.4M; adjusted EBITDA $47.4M (10.1% margin).","Total Lives on Platform 78.6M (from 19.4M); average unique members 41.8M (from 16.3M).","Signed 2 new operating partners (Molina Florida, regional non-profit) and 2 expansions; YTD 6 deals vs target 6-8.","CEO raises 2023 Adj. EBITDA guidance; reaffirms $300M run-rate target exiting 2024.","Redeeming $24.3M of 3.50% convertible notes due 2024 on Oct 13 for cash (100% principal + interest)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-23-000119","json":"https://secwatch.observer/filing/0001628908-23-000119.json","markdown":"https://secwatch.observer/filing/0001628908-23-000119.md","text":"https://secwatch.observer/filing/0001628908-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/0001628908-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/evh-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T13:47:04.398697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d93b0899f58e71b424fc36f5b0ef9709d5b890c","claim":"Evolent Health, Inc. reported the quarter ended June 30, 2023 results: revenue $469.1 million, net income Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million. Guidance raised.","evidence_excerpt":"simpler and more affordable, today announced financial results for the quarter ended June 30, 2023. Highlights from the second quarter 2023 announcement include: • Revenue of $469.1 million, an increase of $149.2 million, or 46.6%, from the three months ended June 30, 2022. • Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/0001628908-23-000119-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$469.1 million"},{"label":"Net income","value":"Net loss attributable to common shareholders of Evolent Health, Inc. of $41.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}